SpringWorks Therapeutics (SWTX) Plunges 3.46% Amid Four-Day Decline
1min read SpringWorks Therapeutics (SWTX) shares fell 3.46% today, marking the fourth consecutive day of decline, with a total drop of 23.24% over the past four days. The stock price hit its lowest level since January 2025, experiencing an intraday decline of 5.19%.
Finepoint Capital LP increased its stake in springworks therapeutics by 15.0% during the fourth quarter, indicating a bullish outlook on the company's future prospects. This move by a significant investor suggests confidence in the company's growth potential and could influence other investors' decisions.
Evercore ISI raised their target price on springworks Therapeutics shares from $60.00 to $65.00, with analyst Cory Kasimov maintaining a buy rating. This adjustment reflects a positive outlook on the company's performance and potential for future growth, which could attract more investors and drive up the stock price.
BofA Securities analyst Alec Stranahan also maintains a buy rating for SpringWorks Therapeutics, keeping the target price at $55. This consistent positive rating from a reputable analyst further supports the bullish sentiment surrounding the company, potentially influencing investor confidence and stock performance.
